广泛性焦虑症的治疗进展

被引：5

作者：

汪春运

机构：

[1] 南京医科大学附属脑科医院

来源：

关键词：

文拉法辛缓释剂; 安慰剂; 空白剂; 艾司西酞普兰; 广泛性焦虑症; 抗精神病药; GAD; 度洛西汀; 丁螺环酮;

D O I：

暂无

中图分类号：

R749.72 [];

学科分类号：

摘要：

<正>当评价广泛性焦虑症GAD疗效时,临床疗效总评量表(CGI)的疗效总评≤2分(有非常多或许多改善)或汉密尔顿焦虑量表(HAMA)分值下降50%定义为有效;HAMA分值≤7分(无或很少焦虑)定义为缓解;不符合GAD诊断标准(症状消退),各方面生活均回到病前功能,定义为恢复[1]。

引用

页码：250 / 254

页数：5

共 5 条

[1] Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder
Hoge, Elizabeth A.
Worthington, John J., III
Kaufman, Rebecca E.
Delong, Hannah R.
Pollack, Mark H.
Simon, Naomi M.
[J]. CNS SPECTRUMS, 2008, 13 (06) : 522 - 527
[2] Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings[J] . Naomi M. Simon,Kathryn M. Connor,Richard T. LeBeau,Elizabeth A. Hoge,John J. Worthington,Wei Zhang,Jonathan R. T. Davidson,Mark H. Pollack.Psychopharmacology . 2008 (4)
[3] Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder:a placebo controlled study. Pollack MH,Simon NM,Zalta AK,et al. Biological Psychiatry . 2006
[4] Generalized anxiety disorder and psychiatric comorbidities such as depression,bipolar disorder,and substance abuse. Simon NM. Journal of Clinical Psychiatry . 2009
[5] Generalized Anxiety Disorder. Canadian Psychiatric Association. Canadian Journal of Psychiatry . 2006